Role of Fixed-Dose Combinations (FDCs) in Indian Prescribing Patterns
Doctors in India widely prescribe Fixed-Dose Combinations (FDCs).
These combinations combine two or more drugs in a single tablet.
Moreover, they simplify treatment and improve patient compliance.
However, many FDCs raise serious concerns about safety and rationality.
Why Doctors Prefer FDCs
FDCs reduce the number of pills patients take daily.
They also lower treatment costs and improve adherence.
Furthermore, pharmaceutical companies promote them heavily in the Indian market.
As a result, FDCs account for a large share of total drug sales in India.
Irrational FDCs Create Major Problems
Many FDCs lack strong scientific evidence.
Some combinations contain drugs that do not work well together.
Others increase the risk of side effects and drug resistance.
Critics argue that several irrational FDCs provide no extra benefit over single drugs.
In addition, they often lead to unnecessary exposure to multiple medicines.
CDSCO Takes Strict Action
The Central Drugs Standard Control Organisation (CDSCO) actively reviews FDCs.
It has banned several irrational combinations over the years.
These bans aim to protect patients from unsafe and ineffective medicines.
Moreover, the regulator continues to evaluate new FDCs before approval.
Despite these efforts, many questionable FDCs still remain available in the market.
Clinical Justification and Evidence
Some FDCs offer clear clinical benefits.
For example, certain anti-tuberculosis and anti-hypertensive combinations work effectively.
However, many others lack proper clinical trials in the Indian population.
Researchers use prescription and sales data to evaluate real-world effectiveness.
Studies show wide variation in how doctors prescribe different FDCs across regions.
Sales and Prescription Data Reveal Trends
Prescription audits indicate high usage of FDCs in private practice.
Sales data from pharmaceutical companies also confirm strong market demand.
Furthermore, certain irrational FDCs continue to generate high revenue.
This creates a gap between regulatory decisions and actual prescribing behavior.
The Way Forward
Doctors need better awareness of rational FDC use.
Medical education should emphasize evidence-based prescribing.
Additionally, regulators must strengthen monitoring systems.
Pharmaceutical companies should focus on clinically justified combinations only.
Overall, Fixed-Dose Combinations play an important role in Indian healthcare.
However, their use requires careful evaluation and strong regulation.
When used appropriately, FDCs improve treatment outcomes.
When misused, they create risks for patients and public health.
Balanced and evidence-based prescribing remains the key to safe medicine use in India.